

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	Graham P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
J		U.S. 6,025,154	10-10-2004	Y. Li et al.	
		U.S. 6,265,184	07-24-2001	P.W. Gray et al.	
		U.S. 6,268,477	07-31-2002	P.W. Gray et al.	
		U.S. 6,488,375	09-10-2002	M. Samson et al.	
		U.S. 6,511,826	01-28-2003	Y. Li et al.	
		U.S. 6,692,938	02-17-2004	M. Samson et al.	
		U.S. 6,743,594	06-01-2004	Y. Li et al.	
		U.S. 6,972,126	12-06-2005	G.P. Allaway et al.	
		U.S. 6,800,447	10-05-2004	M. Samson et al.	
		U.S. 6,800,729	10-05-2004	Y. Li et al.	
	NC		U.S. 5,449,608	09-12-1995	N. Young et al.
		U.S. 6,261,763 B1	07-17-2001	G.P. Allaway et al.	
		U.S. 6,528,625	03-04-2003	L. Wu et al.	
	U.S. 6,930,174	08-16-2005	M. Samson et al.		
	U.S. 6,100,087	08-08-2000	J. Rossi et al.		
	U.S. 5,939,320	08-17-1999	D. Littman et al.		
	U.S. 6,258,527	07-10-2001	D. Littman et al.		
	U.S. 6,258,782	07-10-2001	S. Barney et al.		

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
NC		WO 92/01451	02-06-1992		
		WO 95/16789	06-22-1995		
		WO 97/28258	08-07-1997		
		WO 97/44462	11-27-1997		
		WO 98/18826	05-07-1998		
		WO 01/55439	08-02-2001		

EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/06

\*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

NC - References were not considered with 37 cfr 1.56.

Applicants: Graham P. Allaway et al.  
Serial No.: 09/460,216  
Filed: December 13, 1999  
Exhibit A

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
NC		U.S. 6,692,938	02-17-2004	M. Samson et al.
		U.S. 5,071,964	12-10-1991	M. Dustin et al.
		U.S. 5,091,513	02-25-1992	J. Huston et al.
		U.S. 5,215,913	06-01-1993	M.R. Posner et al.
		U.S. 5,225,539	07-06-1993	G.P. Winter et al.
		U.S. 5,603,933	02-18-1997	V.A. Dwyer et al.
		U.S. 5,668,149	09-16-1997	S. Oroszlan et al.
		U.S. 5,817,767	10-06-1998	G.P. Allaway et al.
		U.S. 5,854,400	12-29-1988	T. Chang et al.
		U.S. 4,886,743	12-12-1989	L.E. Hood et al.
		U.S. 2003/0023044	01-30-2003	Y. Li et al.
		U.S. 2005/0260565	11-24-2005	P.W. Gray et al.
		U.S. 2005/0118677	06-02-2005	P.W. Gray et al.
		U.S. 2003/0166870	09-04-2003	L. Wu et al.
		U.S. 2004/0259785	12-23-2004	C. Combadiere et al.
		U.S. 2003/0195348	10-16-2003	C. Combadiere et al.
		U.S. 2003/0096221	05-22-2003	D. Littman et al.
		U.S. 2003/0003440	01-02-2003	L. Lopalco et al.

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code*Number*Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
NC		WO 02/064612	08-22-2002		
		WO 01/58915	08-16-2001		
		WO 01/58916	08-16-2001		
		WO 96/39437	12-12-1996		
		WO 97/22698	06-26-1997		
		WO 97/44055	11-27-1997		
		WO 97/032019	09-04-1997		

EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Application Number	09/460,216
Filing Date	December 13, 1999
First Named Inventor	Graham P. Allaway et al.
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
NC		U.S. 2002/0150888	10-17-2002	P.W. Gray et al.
		U.S. 2004/0161739	08-19-2004	M. Samson et al.
		U.S. 2004/0230037	11-18-2004	P.W. Gray et al.
		U.S. 2004/0110127	06-10-2004	M. Samson et al.
		U.S. 2005/0154193	07-14-2005	V. Roschke et al.
		U.S. 2003/0100058	05-29-2003	V. Roschke et al.
		U.S. 2003/0166024	09-04-2003	C. Rosen et al.
		U.S. 2004/0151719	08-08-2004	Y. Li et al.
		U.S. 2001/0000241	04-12-2002	Y. Li et al.
		U.S. 2001/0046512	11-29-2001	V.M. Litwin et al.
		U.S. 2002/0048786	04-25-2002	C. Rosen et al.
		U.S. 2002/0061834	05-23-2002	C. Rosen et al.
		U.S. 2002/0110870	08-15-2002	M. Samson et al.
		U.S. 2003/0023044	01-30-2003	Y. Li et al.
		U.S. 2006/0029932	02-09-2006	G.P. Allaway et al.
		U.S. 2006/0140977	6-29-2006	G.P. Allaway et al.
		U.S. 2002/0045161	04-18-2002	G.P. Allaway et al.
		U.S. 2004/0062767	04-01-2004	W.C. Olson et al.

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code*Number*Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
NC		EP 9687002.1	03-01-1996		
		EP 96870102.9	08-06-1996		
		EP 1145721 A2	10-17-2001		
		EP 1146055 A2	10-17-2001		
		EP 1146122 A2	10-17-2001		
		EP 1148126 A2	10-24-2001		
		EP 1148127 A2	10-24-2001		

EXAMINER  
SIGNATURE

DATE CONSIDERED

6/15/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

[illegible]

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Abaza, M.S.I et al., (1992) "Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermined Specificity Obtained By Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) Of Myoglobin", <i>J. Prot. Chem.</i> 11(5):433-443	
		Alexander, H. et al., (1992) "Altering The Antigenicity Of Proteins", <i>Proc. Natl. Acad. Sci.</i> 89:3352-3356	
		Alkhatib et al., (1996) Abstract At 3rd Conference On Retroviruses	
		Allan, J., (1997) "Human Immunodeficiency Virus-Related Infections In Animal Model Systems", In <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp 15-27	
		Allaway, G.P. et al., (1993) "Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination With Antibodies To gp120 Or gp41", <i>AIDS Res Hum Retroviruses</i> 9:581-587	
		Allaway, G.P. et al., (1995) "Expression And Characterization Of CD4-IgG, A Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates", <i>AIDS Res Hum Retrovirus</i> 11:533-539	
		Amara, A. et al., (1997) "HIV Coreceptor Downregulation As Antiviral Principle: SDF-1 $\alpha$ -Dependent Internalization Of The Chemokine Receptor CXCR4 Contributes To Inhibition Of HIV Replication", <i>J. Exp. Med.</i> 186:139-146	
		Arthos, J. et al., (1989) "Identification Of The Residues In Human CD4 Critical For The Binding Of HIV". <i>Cell</i> 57:469-481	
		Ashorn, P.A. et al., (1990) "Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells", <i>J. Virol.</i> 64:2149-2156	
		Attanasio, R. et al., (1991) "Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations In Nonhuman Primate Species", <i>J. Immunol.</i> 146:507-514	
		Baba, M. et al., (1988) "Mechanism Of Inhibitory Effect Of Dextran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In Vitro", <i>Proc. Natl. Acad. Sci.</i> 85:6132-6136	
		Baulerle, P.A. And Huttner, W.B., (1987) "Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification", <i>Cell. Biol.</i> 105:2655-2663	
		Benet et al. (1990) "Pharmacokinetics: The Dynamics Of Drug Absorption, Distribution And Elimination" In <i>Goodman And Gilman's The Pharmacological Basis Of Therapeutics</i> , Gilman Et El., Eds. Pergamon Press, New York, Pp 3-32	

 EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/00

<sup>\*</sup>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Berger, E.A. et al (1996) Abstract No. 002, 8 At Keystone Symposium	
		Berger, E.A., (1997) "HIV Entry And Tropism: The Chemokine Receptor Connection" AIDS 11(Suppl A):S3-S16	
		Berger, E.A. et al., (1999) "Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease", Ann. Rev. Immunol. 17:657-700	
		Bieniasz, P.D. et al., (1997) "HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor", EMBO 16:2599-2609	
		Blanpain, C. et al., (1999) "Multiple Charged And Aromatic Residues In CCR5 Amino-Terminal Domain Are Involved In High Affinity Binding Of Both Chemokines And HIV-1 Env Protein", J. Biol. Chem. 274:34719-34727	
		Brelot, A. et al., (1997) "Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", J. Virol. 71:4744-4751	
		Broder, C.C. et al., (1993) "The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4 Can Be Overcome By A Human Cell Component(s)", Virol. 193:483-491	
		Burkly, L. et al., (1995) "Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion And Infection By An Antibody To CD4 Domain 2 In Combination With Anti-gp-120 Antibodies", J. Virol. 69:4267-4273	
		Burton, D.R. et al., (1994) "Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody", Science 266:1024-1027	
		Busso, M. et al., (1991) "HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro", AIDS 5:1425-1432	
		Camerini, D. et al., (1990) "A CD4 Domain Important For HIV-Mediated Syncytium Formation Lies Outside The Virus Binding Site", Cell 60:747-754	
		Camnack, N., (1999) "Human Immunodeficiency Virus Type 1 Entry And Chemokine Receptors: A New Therapeutic Target", Antivir. Chem. Chemother. 10:53-62	
		Capon, D.J. et al., (1989) "Designing CD4 Immuno adhesions For AIDS Therapy", Nature 337:525-531	

 EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
Attorney Docket No.		50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Chams, V. et al., (1992) "Simple Assay To Screen For Inhibitors Of Interaction Between The Human Immunodeficiency Virus Envelope Glycoprotein And Its Cellular Receptor, CD4", <i>Antimicrob Agents Chemother.</i> 36(2):262-272	
		Chan, D.C. et al., (1998) "Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 gp41 Is An Attractive Drug Target", <i>Proc. Natl. Acad. Sci.</i> 95:15613-15617	
		Chan, D.C. et al., (1998) "HIV Entry And Its Inhibition", <i>Cell</i> 93:681-684	
		Charo, I.F. et al., (1994) "Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing Of The Carboxyl-Terminal Tails", <i>Proc. Natl. Acad. Sci.</i> 91:2752-2756	
		Chen, Z. et al., (1997) "Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry", <i>J. Virol.</i> 71(4):2705-2714	
		Clapham, P.R. et al., (1989) "Soluble CD4 Blocks The Infectivity Of Diverse Strains Of HIV And SIV For T Cells And Monocytes But Not For Brain And Muscle Cells", <i>Nature</i> 337:368-370	
		Clapham, P.R. et al., (1991) "Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2 By Simian Immunodeficiency Virus", <i>Virol.</i> 181:703-715	
		Co. M.S. et al., (1991) "Humanized Antibodies For Antiviral Therapy" <i>Proc. Natl. Acad. Sci.</i> 88:2869-2873	
		Combadiere, C. et al., (1995) "Cloning And Functional Expression Of A Human Eosinophil CC Chemokine Receptor", <i>J. Biol. Chem.</i> 270:16941-16944	
		Combadiere, C. et al., (1996) "Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For MIP-1 $\alpha$ , MIP-1 $\beta$ , And RANTES", <i>J. Leukoc. Biol.</i> 60:147-152	
		Connor, R.I. et al., (1997) "Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals", <i>J. Exp. Med.</i> 185:621-628	
		Cormier, E. G. et al., (2000) "Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 Envelope Glycoprotein gp120", <i>Proc. Natl. Acad. Sci.</i> 97:5762-5767	

 EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Crowe, S.M. et al., (1992) "Human Immunodeficiency Virus-Infected Monocyte-Derived Macrophages Express Surface gp120 And Fuse With CD4 Lymphoid Cells In Vitro: A Possible Mechanism Of T Lymphocyte Depletion In Vivo", <i>Clin. Immunol Immunopathol.</i> 65(2):143-151	
		Crump, M.P. et al., (1997) "Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation From Binding And Inhibition Of HIV-1", <i>EMBO</i> 16:6996-7007	
		Cushman, M. et al., (1991) "Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of Antiviral Potency With Molecular Weight", <i>J. Med. Chem.</i> 34:329-337	
		Dalgleish, A.G. et al., (1984) "The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus" <i>Nature</i> 312:763-766	
		Dalgleish, A.G., (1995) "HIV And CD26", <i>Nat. Med.</i> 1:881-882	
		De Rossi, A. et al., (1995) "Synthetic Peptides From The Principle Neutralizing Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1 Infection Through A CD4-Dependent Mechanism", <i>Virology</i> 184:187-196	
		Dean, M. et al., (1996) "Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CCR5 Structural Gene", <i>Science</i> 273:1856-1862	
		Deen, K.C. et al., (1988) "A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection", <i>Nature</i> 331:82-84	
		Deng, X. et al., (1999) "A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 gp120 Downregulates The Expression And Function Of Chemokine Receptors CCR5 And CXCR4 In Monocytes By Activating The 7-Transmembrane G-Protein-Coupled Receptor FPRL1/LXA4R", <i>Blood</i> 94(4):1165-1173	
		Dettin, M. et al., (2003) "CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation", <i>Biochem. Biophys. Res. Commun.</i> 307(3):640-646	
		Dimitrov, D.S. et al., (1991) "Initial Stages Of HIV-1 Envelope Glycoprotein-Mediated Cell Fusion Monitored By A New Assay Based On Redistribution Of Fluorescent Dyes", <i>AIDS Res Hum Retroviruses</i> 7(10):799-805	
		Ditzel, H.J. et al., (1998) "The CCR5 Receptor Acts As An Alloantigen In CCR5Δ32 Homozygous Individuals: Identification Of Chemokine And HIV-1 Blocking Human Antibodies", <i>Proc. Natl. Acad. Sci.</i> 95(9):5241-5245	

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

10/15/16

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.



<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Donzella, G.A. et al., (1998) "AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor", <i>Nat. Med.</i> 4:72-77	
		Doranz, B.J. et al., (1997) "Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 71:6305-6314	
		Dragic, T. et al., (1992) "Complementation Of Murine Cells For Human Immunodeficiency Virus Envelope/CD4-Mediated Fusion In Human/Murine Heterokaryons", <i>J. Virol.</i> 66(8):4794-4802	
		Dragic, T.V. et al., (1993) "Different Requirements For Membrane Fusion Mediated By The Envelopes Of Human Immunodeficiency Virus Types 1 And 2", <i>J. Virol.</i> 67(4):2355-2359	
		Dragic, T.V. et al., (1995) "Proteinase-Resistant Factors In Human Erythrocyte Membranes Mediate CD-4 Dependent Fusion With Cells Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoproteins", <i>J. Virol.</i> 69:1013-1018	
		Dragic, T.V. et al., (1998) "Amino-Terminal Substitutions In The CCR5 Coreceptor Impair gp120 Binding And Human Immunodeficiency Virus Type 1 Entry" <i>J. Virol.</i> 72(1):279-285	
		Dragic, T.V. et al., (2000) "A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5", <i>Proc. Natl. Acad. Sci.</i> 97(10):5639-5644	
		Ebadi, M., (1998) "The Pharmacokinetic Basis Of Therapeutics", In CRC Desk Reference Of Clinical Pharmacology, CRC Press LLC, Boca Raton, Pp. 1-7	
		Eckert, D.M. et al., (1999) "Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket", <i>Cell</i> 99:103-115	
		Eugene-Olsen, J. et al., (1997) "Heterozygosity For A Deletion In The CKR-5 Gene Leads To Prolonged AIDS-Free Survival And Slower CD4 T-Cell Decline In A Cohort Of HIV-Seropositive Individuals", <i>AIDS</i> 11:305-310	
		Farzan, M. et al., (1998) "A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And Mediates Association Between gp120 And CCR5", <i>J. Virol.</i> 72:1160-1164	
		Farzan, M. et al., (1999) "Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry", <i>Cell</i> 96:667-676	
✓		Farzan, M. et al., (2000) "A Tyrosine-Sulfated Peptide Based On The N Terminus Of CCR5 Interacts With A CD4-Enhanced Epitope Of The HIV-1 gp 120 Envelope Glycoprotein And Inhibits HIV-1 Entry", <i>J. Biol. Chem.</i> 275:33416-33521	

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

10/15/00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Application Number</b>	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Filing Date</b>	December 13, 1999
				<b>First Named Inventor</b>	Graham P. Allaway et al.
				<b>Art Unit</b>	1648
				<b>Examiner Name</b>	Jeffrey S. Parkin
				<b>Attorney Docket No.</b>	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
NC		Feng, Y. et al., (1996) Abstract No. 116,21 At Keystone Symposium			
		Ferrer, M. et al., (1999) "Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural Binding Elements", <i>Nature Struct. Biol.</i> 6:953-959			
		Fouchier, R.A. et al., (1994) "HIV-1 Macrophage Tropism Is Determined At Multiple Levels Of The Viral Replication Cycle", <i>J. Clin. Invest.</i> 94:1806-1814			
		Fouts, T.R. et al., (1997) "Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies Correlates With Antibody Binding To The Oligomeric Form Of The Envelope Glycoprotein Complex", <i>J. Virol.</i> 71:2779-2785			
		Freed, E.O. et al., (1991) "Identification Of Conserved Residues In The Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved In Fusion", <i>AIDS Res. Hum. Retroviruses</i> 7(10):807-811			
		Fradd, F. and Mary, M.E. (1989) "AIDS Vaccines: An Investor's Guide By Shearman Lehman Hutton", Page 10 (Fig. 2)			
		Frazer, J.K. and Capra, J.D., (1999) "Immunoglobulins: Structure And Function" Fundamental Immunology, 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp. 37-74			
		Furuta, R.A. et al., (1998) "Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41", <i>Nature Struct. Biol.</i> 5(4):276-279			
		Gauduin, M.C. et al., (1996) "Effective Ex Vivo Neutralization Of Human Immunodeficiency Virus Type 1 in Plasma By Recombinant Immunoglobulin Molecules", <i>J. Virol.</i> 70:2586-2592			
		Gauduin, M.C. et al., (1997) "Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary Isolates Of HIV-1", <i>Nat. Med.</i> 3:1389-1393			
		Gharpade, A. et al., (1998) "Role Of The $\beta$ -Chemokine Receptors CCR3 And CCR5 In Human Immunodeficiency Virus Type 1 Infection Of Monocytes And Microglia", <i>J. Virol.</i> 72:3351-3361			
		Golding, H. et al., (1992) "LFA-1 Adhesion Molecules Are Not Involved In The Early Stages Of HIV-1 env-Mediated Cell Membrane Fusion", <i>AIDS Res. Hum. Retroviruses</i> 8:1593-1598			
		Graham, B.S. et al., (1995) "Candidate AIDS Vaccines", <i>New Engl. J. Med.</i> 333:1331-1339			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/15/06			
<p><sup>1</sup>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Application Number</b>	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Filing Date</b>	December 13, 1999
				<b>First Named Inventor</b>	Graham P. Allaway et al.
				<b>Art Unit</b>	1648
				<b>Examiner Name</b>	Jeffrey S. Parkin
				<b>Attorney Docket No.</b>	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials<sup>1</sup></b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
NC		Greene, E. et al., (2001) "Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals", <i>Human Immunol.</i> 62(2):143-145			
		Harouse, J.M. et al., (1991) "Inhibition Of Entry Of HIV-1 In Neural Cell Lines By Antibodies Against Galactosyl Ceramide", <i>Science</i> , 253:320-323			
		Harrington, R.D. And Geballe, A.P., (1993) "Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line", <i>J. Virol</i> 67:5939-5947			
		He, J. et al., (1997) "CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia", <i>Nature</i> 385: 645-649			
		Heath, et al., (1997) "Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal Antibody", <i>J. Clin. Invest.</i> 99:178-184			
		Heidenreich, O. et al., (1995) "Application Of Antisense Technology To Therapeutics", <i>Mol. Med. Today</i> 1:128-133			
		Hildreth, J.E. et al., (1989) "Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation" <i>Science</i> 244:1075-1078			
		Hill, C.M. et al., (1998) "The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor For Diverse Human And Simian Immunodeficiency Virus Envelope Glycoproteins", <i>Virology</i> 248:357-371			
		Hirata, Y., (1989) "Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies", <i>J. Immun.</i> 143(9):2900-2906			
		Hirsch, M.S. et al., (1997) "Antiretroviral Therapy" In <i>AIDS: Biology, Diagnosis, Treatment, And Prevention</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp. 495-508			
		Hwang, S. et al., (1991) "Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1," <i>Science</i> 253:71-74			
		Jacobson, J.M. et al., (1993) "Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection", <i>J. Infect. Dis.</i> 168:298-305			
		Jacobson, J. et al., (1999) "Results Of A Phase I Trial Of Single-Dose PRO 542, A Novel Inhibitor Of HIV Entry", Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14			
		Ji, H. et al., (1999) "Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In Membrane Fusion", <i>J. Virol</i> 73:8578-8586			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/15/06			
<p>*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce</b>		<b>Application Number</b>	<b>09/460,216</b>
		<b>Patent and Trademark Office</b>		<b>Filing Date</b>	<b>December 13, 1999</b>
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>First Named Inventor</b>	<b>Graham P. Allaway et al.</b>
				<b>Art Unit</b>	<b>1648</b>
				<b>Examiner Name</b>	<b>Jeffrey S. Parkin</b>
				<b>Attorney Docket No.</b>	<b>50875-F-PCT US/JPW/AG/LAD</b>
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No.†</b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
NC		Jiang, S. et al., (1993). "HIV-1 Inhibition By A Peptide", <i>Nature</i> 365: 113			
		Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", <i>Biotech. Therap.</i> 2:31-48			
		Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" <i>Antibiot. Chemother.</i> 46:25-37			
		Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" <i>J. Cell Sci.</i> 28:167-177			
		Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", <i>Nat. Med.</i> 4:1302-1307			
		Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", <i>Eur. J. Immunol.</i> 30(4):1162-1171			
		Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", <i>Chem. Pharm. Bull (Tokyo)</i> 48(2):308-309			
		Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", <i>Immunology.</i> 8:263-268			
		Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing Human Antibody", <i>Nature</i> 393:648-659			
		Laal, S. et al., (1994) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies", <i>J. Virol</i> 68:4001-4008			
		Lacasse, R.A. et al., (1999) "Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV", <i>Science</i> 283:357-362			
		Lee, B. et al., (1999) "Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In Chemokine Coreceptor Function", <i>J. Biol. Chem.</i> 274:9617-9626			
		Lehner, T. et al., (2001) "Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian Immunodeficiency Or HIV Infectivity", <i>J. Immunol.</i> 166(12):7446-7455			
		Li, A. et al., (1997) "Synergistic Neutralization Of A Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies Or Hyperimmune Globulins", <i>AIDS Res. Hum. Retroviruses</i> 13:647-56			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/15/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡Applicant is to place a checkmark here if English language Translation is attached.					

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Application Number</b>	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Filing Date</b>	December 13, 1999
				<b>First Named Inventor</b>	Graham P. Allaway et al.
				<b>Art Unit</b>	1648
				<b>Examiner Name</b>	Jeffrey S. Parkin
				<b>Attorney Docket No.</b>	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials<sup>2</sup></b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
NC		Li, A.H. et al., (1998) "Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-Vpu+ By Triple And Quadruple Combination Of Human Monoclonal Antibodies And High-Titer Antihuman Immunodeficiency Virus Type 1 Immunoglobulins", <i>J. Virol.</i> 72:3235-3240			
		Mack, M. et al., (1998) "Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV Infectivity", <i>J. Exp. Med.</i> 187:1215-1224			
		Mackay, C.R., (1996) "Chemokine Receptors And T Cell Chemotaxis", <i>J. Exp. Med.</i> 184: 799-802			
		Maddon, P.J. et al., (1986) "The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain", <i>Cell</i> 47:333-348			
		Markosyan, R.M. et al., (2002) "The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain", <i>Virology</i> 302:174-184			
		Mateu, M.G. et al. (1992) "Non-Additive Effects Of Multiple Amino Acid Substitutions On Antigen-Antibody Recognition", <i>European J. Immunol.</i> 22(6):1385-1389			
		Max, E., "Immunoglobulins: Molecular Genetics" Fundamental Immunology, 4th Edition. Lippincott-Raven Publishers, Philadelphia, 1999 Pp. 11-182			
		Mitsuya, H. et al., (1985) "Protection Of T Cells Against Infectivity And Cytopathic Effect Of HTLV-III In Vitro", <i>Retroviruses In Human Lymphoma Leukemia Japan Sci. Soc. Press, Tokyo/VNU Science Press, Utrecht</i> Pp.277-288			
		Mittler, R.S. et al. (1989) "Synergism Between HIV gp120 And gp120-Specific Antibody In Blocking Human T. Cell Activation", <i>Science</i> 245:1380-1382			
		Mohan, P. et al., (1992) "Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors", <i>Antiviral Res.</i> 18:139-150			
		Mosier, D.E., (1990) "Immunodeficient Mice Xenografted With Human Lymphoid Cells: New Models For In-Vivo Studies Of Human Immunobiology And Infectious Diseases", <i>J. Clin. Immunol.</i> 10(4):185-191			
		Nagasawa, T. et al., (1994) "Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor", <i>Proc. Natl. Acad. Sci.</i> 91:2305-2309			
		Nagashima, K.A. et al., (2001) "Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking Virus-Cell And Cell-Cell Fusion", <i>J. Infect. Dis.</i> 183:1121-1125			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 6/16/06			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Filing Date	December 13, 1999
				First Named Inventor	Graham P. Allaway et al.
				Art Unit	1648
				Examiner Name	Jeffrey S. Parkin
				Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
NC		Nakano, T. et al., (1995) "Vascular Smooth Muscle Cell-Derived, Gla-Containing Growth-Potentiating Factor For Ca(2+)-Mobilizing Growth Factors", <i>J. Biol. Chem.</i> 270(11):5702-5705			
		Neote, K. et al., (1993) "Molecular Cloning, Functional Expression, And Signaling Characteristics Of A C-C Chemokine Receptor", <i>Cell</i> 72:415-425			
		O'Brien, W.A. et al., (1990) "HIV-1 Tropism For Mononuclear Phagocytes Can Be Determined By Regions Of gp120 Outside Of The CD4-Binding Domain", <i>Nature</i> 348:69-73			
		Olson, W.C. et al., (1999) "Differential Inhibition Of Human Immunodeficiency Virus Type 1 Fusion, gp 120 Binding And CC-Chemokine Activity Of Monoclonal Antibodies To CCR5", <i>J. Virol.</i> 73:4145-4155			
		Oppermann, M. (2004) "Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation", <i>Cell. Signal.</i> 16:1201-1210			
		Parren, P.W. et al., (2001) "Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum Levels Giving Complete Neutralization In Vitro" <i>J. Virol.</i> 75:8340-8347			
		Partidos, C. et al., (1992) "The Effect Of Orientation Of Epitopes On The Immunogenicity Of Chimeric Synthetic Peptides Representing Measles Virus Protein Sequences", <i>Molecular Immunology</i> 29(5):651-658			
		Peden, K. et al., (1991) "Changes In Growth Properties On Passage In Tissue Culture Of Viruses Derived From Infectious Molecular Clones Of HIV-1LAI, HIV-1MAL, And HIV-1ELI", <i>Virol.</i> 185:661-672			
		Poignard, P. et al., (1999) "Neutralizing Antibodies Have Limited Effects On The Control Of Established HIV-1 Infection In Vivo", <i>Immunity</i> 10:431-438			
		Posner, M.R. et al., (1993) "Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120", <i>J. Acq. Immune Defic. Synd.</i> 6:7-14			
		Power, C.A. et al., (1995) "Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor cDNA From A Human Basophilic Cell Line", <i>J. Biol. Chem.</i> 270:19495-19500			
		Proudfoot, A.E. et al., (1996) "Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methionine Produces A Potent Antagonist", <i>J. Biol. Chem.</i> 271:2599-2603			
		Queen, C. et al., (1989) "A Humanized Antibody That Binds To The Interleukin 2 Receptor", <i>Proc. Natl. Acad. Sci</i> 86:10029-10033			
EXAMINER SIGNATURE		DATE CONSIDERED 10/15/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a checkmark here if English language Translation is attached.					

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Filing Date	December 13, 1999
				First Named Inventor	Graham P. Allaway et al.
				Art Unit	1648
				Examiner Name	Jeffrey S. Parkin
				Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
NC		Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 72:3464-3468			
		Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1 $\beta$ , And MIP-1 $\alpha$ ", <i>J. Biol. Chem.</i> 271:1761-17166			
		Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope 'gp120-gp41'", <i>J. Virol.</i> 69:2233-2239			
		Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", <i>Cell</i> 87:437-446			
		Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", <i>Cell. Immunol.</i> 189:160-168			
		Rudikoff, S. et al., (1982) "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci.</i> 79:1979-1983			
		Rusche, J.R. et al., (1988) "Antibodies That Inhibit Fusion Of Human Immunodeficiency Virus-Infected Cells Bind A 24-Amino Acid Sequence Of The Viral Envelope gp120", <i>Proc. Natl. Acad. Sci.</i> 85:3198-3202			
		Sagg, M. (1997) "Clinical Spectrum Of Human Immunodeficiency Virus Diseases" <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , Lippincott-Raven Publishers, Philadelphia, Pp. 203-213			
		Sandberg, J. and Slikker, W., (1995) "Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides", <i>FASEB J.</i> 9:1157-1163			
		Sandstorm, E.G. And Kaplan, J.C., (1987) "Antiviral Therapy In AIDS: Clinical Pharmacological Properties And Therapeutic Experience To Date", <i>Drugs</i> 34:372-390			
		Sato, A.I. et al., (1992) "Anti-CD7 Reagents Inhibit HIV-1 Induced Syncytium Formation," International Conference On AIDS. 81. PA5 Poa 2017			
		Sato, A.I. et al., (1994) "Identification Of CD7 Glycoprotein As An Accessory Molecule In HIV-1 Mediated Syncytium Formation And Cell Free Infection", <i>J. Immunol.</i> 152:5142-5152			
		Sato, A.I. et al., (1995) "A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice", <i>Antivir. Res.</i> 27:151-163			
EXAMINER SIGNATURE		DATE CONSIDERED 10/15/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a checkmark here if English language Translation is attached.					

<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Schanberg, L.W. et al., (1995) "Characterization Of Human CD7 Transgenic Mice", <i>J. Of Immunol.</i> 155: 2407-2418	
		Schmidtayerova, H. et al., (1993) "Characterization Of HIV1-PAR, A Macrophage-Tropic Strain: Cell Tropism, Virus/Cell Entry And Nucleotide Sequence Of The Envelope Glycoprotein. <i>Research In Virology</i> 144(1):21-26	
		Schols, D. et al., (1990) "Dextran Sulfate And Other Olyanionic Anti-HIV Compounds Specifically Interact With The Viral gp120 Glycoprotein Expressed By T-Cells Persistently Infected With HIV-1", <i>Virol.</i> 175:556-561	
		Schols, D. et al., (1991) "Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human Immunodeficiency Virus Replication", <i>J. Acq. Immune Defic. Synd.</i> 4:677-685	
		Schols, D. et al., (1999) "CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity", <i>Antiviral Res.</i> 30:175-187	
		Sinangil, F. et al., (1988) "Quantitative Measurement Of Fusion Between Human Immunodeficiency Virus And Cultured Cells Using Membrane Fluorescence Dequenching", <i>FEB</i> 239(1):88-92	
		Sommerfelt, M.A. et al., (1995) "Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid And Monocytoid Cells", <i>J. Gen. Virol.</i> 76:1345-1352	
		Stein, D.S. et al., (1993) "Immune-Based Therapeutics: Scientific Rationale And Promising Approaches To The Treatment Of The Human Immunodeficiency Virus-Infected Individual", <i>Clin. Infect. Dis.</i> 17:749-771	
		Steinberger, P. et al., (2000) "Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody", <i>J. Biol. Chem.</i> 275:36073-36078	
		Stewart, G.J., (1997) "Increased Frequency Of CCR-5 Δ32 Heterozygotes Among Long-Term Non-Progressors With HIV-1 Infection", <i>AIDS</i> 11:1833-1838	
		Strizki, J.M. et al., (1997) "A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency Virus Type 1 Isolates HIV-1 89.6 But Not The T-Tropic Isolate HIV-1 Hxb", <i>J. Virol.</i> 71:5678-5683	
		Su, S.B. et al., (1996) "Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On Various Types Of Leukocytes" <i>J. Leukoc. Biol.</i> 60:658-666	
		Szabo, G. Jr. et al., (1993) "Specific Disengagement Of Cell-Bound Anti-LAM-1 (Anti-Selectin) Antibodies By Aurintricarboxylic Acid," <i>Molecular Immunology</i> 30(18):1689-1694	

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

10/15/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.



<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	Application Number	09/460,216
	Filing Date	December 13, 1999
	First Named Inventor	Graham P. Allaway et al.
	Art Unit	1648
	Examiner Name	Jeffrey S. Parkin
	Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NC		Thali, M. et al., (1992) "Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human Immunodeficiency Virus gp120 Envelope Glycoprotein", <i>J. Acq. Immun. Defic. Synd.</i> 5:591-599	
		Tilley, S. A. (1992) "Synergistic Neutralization Of HIV-1 By Human Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site gp120", <i>AIDS Research And Human Retroviruses</i> 80:4:461-467	
		Tilley, S. A. et al., (1991) "Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three Distinct Epitope Clusters Of gp120", <i>Sixieme Colloque Des Cent Gardes.</i> 211-216	
		Travis, B.M. et al., (1992) "Functional Roles Of The V3 Hypervariable Region Of HIV-1 gp160 In The Processing Of gp160 And In The Formation Of Syncytia In CD4-Positive Cells", <i>Virol.</i> 186:313-317	
		Tremblay, C.L. et al. (2000) "Strong In Vitro Synergy Observed Between The Fusion Inhibitor T-20 And A CXCR4 Blocker AMD-3100.", 7th Conference On Retroviruses And Opportunistic Infections Abstract 500	
		Tremblay, C.L. et al., (1999) "Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker AMD-3100", <i>J. Acq. Immun. Defici. Synd.</i> 25(2)99-102	
		Trkola, A. et al., (2001) "Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140", <i>J. Virol.</i> 75:579-588	
		Trkola, A et al (1999) "Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies And Tetrameric CD4-IgG", <i>J. Virol.</i> 69:6609-6617	
		Trkola, A. et al., (1998) "Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD4-based Reagents Is Independent Of Coreceptor Usage", <i>J. Virol.</i> 72:1876-1885	
		Tulip, W.R. et al., (1992) "Crystal Structures Of Two Mutant Nerraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface", <i>J. Mol. Biol.</i> 227:149-159	
		Valentin, A. et al., (1990) "The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncytia Formation In Monocytoid And T Cells", <i>J. Immunol.</i> 144:934-937	
		Valenzuela, A. et al., (1997) "Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And Independent Binding Of Virus To Cells", <i>J. Virol.</i> 71(11):8289-8298	
		Vanini, S. et al., (1992) "Discrete Regions Of HIV-1 gp41 Defined By Syncytia-Inhibiting Affinity-Purified Human Antibodies", <i>AIDS</i> 7:167-174	

 EXAMINER  
SIGNATURE

DATE CONSIDERED

10/15/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Application Number</b>	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Filing Date</b>	December 13, 1999
				<b>First Named Inventor</b>	Graham P. Allaway et al.
				<b>Art Unit</b>	1648
				<b>Examiner Name</b>	Jeffrey S. Parkin
				<b>Attorney Docket No.</b>	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
Nc		Verrier, F.C. et al., (1997) "Antibodies To Several Conformation-Dependent Epitopes Of gp120/gp41 Inhibit CCR-5-Dependent Cell-To-Cell Fusion Mediated By The Native Envelope Glycoprotein Of A Primary Macrophage-Tropic HIV-1 Isolate", <i>Proc. Natl. Acad. Sci.</i> 94:9326-9331			
		Vijh-Warrier, S. (1996) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A Chimpanzee Monoclonal Antibody Against The V2 Domain Of gp120 In Combination With Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site", <i>J. Virol.</i> 70:4466-4473			
		Vila-Coro, A.J. et al., (2000) "HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization", <i>Proc. Natl. Acad. Sci.</i> 97(7):3388-3393			
		Vita, C. et al., (1999) "Rational Engineering Of A Miniprotein That Reproduces The Core Of The CD4 Site Interacting With HIV-1 Envelope Glycoprotein", <i>Proc. Natl. Acad. Sci.</i> 96:13091-13096			
		Wang, Z.Q. et al., (1994) "Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 And gp120-Specific Antibodies From AIDS Patients", <i>Eur. J. Immunol.</i> 24:1553-1557			
		Wanda, P.E., And Smith, J.D., (1982) "A General Method For Heterokaryon Detection Using Resonance Energy Transfer And A Fluorescence-Activated Cell Sorter", <i>J. Histochem. &amp; Cytochem.</i> 30(12):1297-1300			
		Weinhold, K.J., et al., (1989) "HIV-1 gp120-Mediated Immune Suppression And Lymphocyte Destruction In The Absence Of Viral Infection", <i>J. Immunol.</i> 142:3091-3097			
		Wild, C. et al., (1992) "A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure And Viral Inhibition", <i>Proc. Natl. Acad. Sci.</i> 89:10537-10541			
		Wild, C. et al., (1993) "A Synthetic Peptide From HIV-1 gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion", <i>AIDS Res. Hum. Retroviruses</i> 9:1051-1053			
		Wild, C. et al., (1994) "Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are Potent Inhibitors Of Virus Infection", <i>Proc. Natl. Acad. Sci.</i> 91:9770-9774			
		Wild, C. et al., (1995) "The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine Zipper Structure", <i>AIDS Res. Hum. Retroviruses</i> 11:323-325			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/15/06			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Application Number</b>	09/460,216
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Filing Date</b>	December 13, 1999
				<b>First Named Inventor</b>	Graham P. Allaway et al.
				<b>Art Unit</b>	1648
				<b>Examiner Name</b>	Jeffrey S. Parkin
				<b>Attorney Docket No.</b>	50875-F-PCT US/JPW/AG/LAD
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>			<b>T<sup>2</sup></b>
NC		Wu, L. et al., (1997) "Interaction Of Chemokine Receptor CCR5 With Its Ligands: Multiple Domains For HIV-1 gp120 Binding And A Single Domain For Chemokine Binding", <i>J. Exper. Med.</i> 186(8):1373-1381			
↓		Yamagami, S. et al., (1994) "cDNA Cloning And Functional Expression Of Human Monocyte Chemoattractant Protein 1 Receptor", <i>Biochem. Biophys. Res. Commun.</i> 212:1156-1162			
		Ylisastigui, L. et al., (1998) "Synthetic Full Length And Truncated RANTES Inhibit HIV-1 Infection Or Primary Macrophages", <i>AIDS</i> 12:977-984			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/15/06			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p>					